Monash IVF Group Ltd (ASX:MVF) has taken the unusual step of cancelling executive bonuses after two high-profile embryo-transfer errors disclosed earlier this year shook confidence in one of Australia’s biggest fertility networks.
The move follows a bruising period for the company that saw CEO Michael Knaap and long-time chief operating officer Hamish Hamilton depart, an independent investigation by Fiona McLeod AO SC, and a slide in investor sentiment.
Board takes a hard line
According to the FY25 annual report, the board withheld all short-term incentive (STI) payments for executives, including acting CEO Malik Jainudeen, “before the usual formulaic outcomes were known”. It also cancelled Knaap’s deferred FY24 bonus and introduced a new “modifier” policy that allows directors to reduce future bonuses in cases of serious adverse events or material reputational, financial, or safety impacts.
Knaap’s total FY25 remuneration was $673,310, including $334,000 in termination benefits. Jainudeen’s fixed pay was about $401,000, topped up with a temporary “higher-duties” allowance of $228,000 per year while he leads the company through the transition.
Governance after the mix-ups
Monash IVF’s reputation took a hit after two separate embryo-mix-up incidents at its Brisbane and Clayton (Victoria) clinics. The first incident, which was disclosed in April but occurred in 2023, involved an embryo transferred to the wrong patient, resulting in a child born to another couple. The second saw a patient receive her own embryo instead of her partner’s.
Read more: Monash IVF CEO resigns amid embryo mix-up scandals as calls for IVF regulation grow
Both cases prompted a wide-ranging independent review, with McLeod’s report confirming human error as the primary cause and highlighting IT-system limitations at the Clayton site. The company has accepted all recommendations and says implementation is under way.
Shares fell almost 30% after the second incident in June, underscoring how reputational events can quickly erode value in the healthcare sector. The board has since apologised publicly, tightened protocols and added new system controls across its laboratories.
Setting a precedent for the sector
The bonus cancellations mark a sharp break from the past, signalling that clinical safety failures will now directly affect executive pay. The new modifier — essentially a formal link between patient safety and remuneration — could become a model for governance in Australia’s assisted-reproduction industry.
While incentive plans have traditionally been driven by financial metrics such as earnings and market share, Monash’s decision embeds non-financial criteria that speak directly to patient outcomes. It is a move that aligns the executive team’s interests with the company’s duty of care — and acknowledges that operational lapses can inflict lasting financial damage.
The governance tightening also comes as regulators weigh whether IVF providers should face stronger national oversight. Industry bodies have already called for a clearer accreditation framework following Monash’s incidents and a class-action settlement earlier in the year.
What investors should watch
For investors, the main question is whether these measures will restore trust. The company still faces softer domestic IVF demand and reputational headwinds that may weigh on near-term earnings. Monash has guided for FY26 underlying net profit after tax (NPAT) of $20 million to $23 million — down from $27.4 million — as it absorbs higher compliance costs and works through the fallout from the incidents.
Yet the longer-term fundamentals remain attractive: rising fertility demand, growth across Southeast Asia and new genetic-testing services. If Monash can demonstrate that its governance reset translates into fewer risks and more consistent performance, it may turn a reputational crisis into a chance to lead on safety standards.
By docking bonuses and formalising a risk-based pay modifier, the board has drawn a clear link between executive reward and patient safety. For a sector built on trust, that connection may prove just as important to long-term value as the next clinical success rate.